Mabwell (Shanghai) Bioscience Co., Ltd. (SHA:688062)

China flag China · Delayed Price · Currency is CNY
34.87
-0.20 (-0.57%)
Apr 29, 2026, 1:25 PM CST
63.79%
Market Cap 15.12B
Revenue (ttm) 662.52M
Net Income (ttm) -969.33M
Shares Out 445.54M
EPS (ttm) -2.43
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,746,848
Average Volume 9,463,760
Open 35.46
Previous Close 35.07
Day's Range 34.73 - 35.68
52-Week Range 16.78 - 63.59
Beta 0.76
RSI 41.60
Earnings Date Apr 29, 2026

About SHA:688062

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 1,325
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688062
Full Company Profile

Financial Performance

In 2025, SHA:688062's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial Statements

News

There is no news available yet.